Work

Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program

Year: 2009

Type: article

Abstract: Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 microg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.22188

Authors: Malcolm A. Smith, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Min H. Kang, C. Patrick Reynolds, John M. Maris, Amy E. Watkins, Peter J. Houghton

Institutions: National Institutes of Health, National Cancer Institute, St. Jude Children's Research Hospital, Alfred I. duPont Hospital for Children, Children's Hospital at Montefiore, Duke University, Duke Medical Center, Children's Cancer Institute Australia, Texas Tech University Health Sciences Center, Children's Hospital of Philadelphia, University of Pennsylvania

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1215897271, Pediatric Preclinical Testing Program, G1628177865, G5277985768, G609259107, SPORE in Brain Cancer, Cancer Center Support Grant (CCSG)

OpenAlex ID: W2059602829

FWCI: 2.51

Cites: 23

Cited by: 15

Related to: 10